Alphamab Oncology (HKSE:09966) Days Sales Outstanding : 34.02 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Days Sales Outstanding?

Alphamab Oncology's average Accounts Receivable for the six months ended in Dec. 2023 was HK$16.8 Mil. Alphamab Oncology's Revenue for the six months ended in Dec. 2023 was HK$90.0 Mil. Hence, Alphamab Oncology's Days Sales Outstanding for the six months ended in Dec. 2023 was 34.02.

The historical rank and industry rank for Alphamab Oncology's Days Sales Outstanding or its related term are showing as below:

HKSE:09966' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.01 Med: 19.14 Max: 26.07
Current: 25.86

During the past 7 years, Alphamab Oncology's highest Days Sales Outstanding was 26.07. The lowest was 19.01. And the median was 19.14.

HKSE:09966's Days Sales Outstanding is ranked better than
87.71% of 887 companies
in the Biotechnology industry
Industry Median: 72.66 vs HKSE:09966: 25.86

Alphamab Oncology's Days Sales Outstanding increased from Dec. 2022 (25.03) to Dec. 2023 (34.02).

Alphamab Oncology Days Sales Outstanding Historical Data

The historical data trend for Alphamab Oncology's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Days Sales Outstanding Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

19.01

26.07

19.14

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial								9.51	38.81	25.03	26.33	34.02

Competitive Comparison of Alphamab Oncology's Days Sales Outstanding

For the Biotechnology subindustry, Alphamab Oncology's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Days Sales Outstanding falls into.

Alphamab Oncology Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Alphamab Oncology's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (17.298	+	7.8)	/	2 )	/	239.29	*	365
=	12.549					/	239.29	*	365
=	19.14

Alphamab Oncology's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (25.764	+	7.8)	/	2 )	/	90.028	*	365 / 2
=	16.782					/	90.028	*	365 / 2
=	34.02

Alphamab Oncology (HKSE:09966) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Alphamab Oncology Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Executives

South Dakota Trust Company Llc	2301 Trustee
Xu Ting	2305 Beneficiary of a trust
Liu Yang	2307 Founder of a discretionary trust who can infl
Rubymab Ltd.	2101 Beneficial owner
Pang Kee Chan Hebert
Highbury Investment Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Advantech Capital Ii Investment Partners Limited
Advantech Capital Ii Alphamab Partnership L.p.
Advantech Capital Partners Ii Limited
Advantech Capital Investment I Limited
Advantech Capital Ii Master Investment Limited
Advantech Capital Ii L.p.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines